HealthTree Logo
search more_vert
person Sign In / Create Account
ASH 2023: IDH2 Mutation Affects Bone Marrow And AML Cells
Posted: Feb 06, 2024
ASH 2023: IDH2 Mutation Affects Bone Marrow And AML Cells image

At the ASH 2023 Conference held in December, Jane Liesveld, a physician from the University of Rochester Medical Center, shared results from a collaboration concerning the IDH2 gene mutation. Watch the video below or continue reading to hear more about Dr. Liesveld's important research.


The isocitrate dehydrogenase 2 (IDH2) mutation impairs a cell’s immune system and its macrophages (a type of white blood cell) that is necessary for eliminating diseased cells. This allows the cancerous cells to continue to grow in the bone marrow and lead to inflammatory changes. The IDH mutation increases in frequency with age and can lead to greater implications than previously understood.

IDH2 Mutation Can Lead To AML

This mutation occurs in 15%-20% of AML patients and has an affect on how genes are expressed. To better understand this mutation, murine cells were examined for their manifestation and survival. This collaboration discovered that when this mutation is present, MDS often evolves into AML. It also examined how AML cells break down (metabolize) in the body and how this mutation affects stem cells. More research is needed to understand how IDH2 genes grow and produce energy (metabolic substrates).

Promising Future

This abstract study was initiated to begin to better understand this gene mutaiton and its affects on the AML cell. Targeting IDH2 is a future treatment goal.

See these articles for further information on IDH2:

Understanding the IDH1 and IDH2 mutations

Recent Drug Approvals For AML Part 2: IDH Inhibitors

Common Genetic Mutations Found In AML

HealthTree CureHub

At HealthTree, we believe that patients are powerful and have an opportunity to contribute to research in an incredibly unique way. HealthTree Cure Hub empowers patients with the knowledge to actively participate in their health journeys while providing researchers with valuable insights from real-world experiences. HealthTree Cure Hub connects patients and researchers to not only accelerate the development of innovative treatments but also lays the foundation for a future where more educated patients and research leads to more effective and personalized cures. Visit HealthTree Cure Hub today to become an active participant in your care and contribute your unique experience to researchers to move closer to a cure. 

For assistance setting up your HealthTree Cure Hub account, reach out to our patient navigation team by phone: 1-800-709-1113 or email:

The author Lisa Foster

about the author
Lisa Foster

Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home. 

Get the latest thought leadership on Acute Myeloid Leukemia delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Acute Myeloid Leukemia Newsletter" for Acute Myeloid Leukemia news, life with Acute Myeloid Leukemia stories, Acute Myeloid Leukemia clinical trials, Acute Myeloid Leukemia 101 articles and events with Acute Myeloid Leukemia experts.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Astellas Pharma

Follow Us

facebook twitter